| Aluminium | |
| Aluminium, | |
| Whole blood sample sent (do not centrifuge), Plain white 10ml bottle. | |
| This test is referred to another centre for analysis: Department of Clinical Chemistry Northern General Hospital Herries Road Sheffield S5 7AU Tel: 0114 243 4343 Fax: 0114 256 0472 | |
| Used in the investigation of aluminium toxicity | |
| Contact referal laboratory | |
| Contact referal laboratory | |
| N/A | |
| N/A | 
Blood Science Test Repertoire
| Arsenic | |
| Arsenic, ARS | |
| Blood: 7.5ml EDTA (red top) tube Urine: 20ml sterile universal container | |
| This test is referred to another lab for analysis:Medical Toxicology Unit 3rd Floor, Block 7 South Wing St Thomas' Hospital Lambeth Palace Road London SE1 7EH Tel: 020 7188 8783 | |
| Used in the investigation of arsenic poisoning | |
| Contact referal laboratory | |
| Contact referal laboratory | |
| N/A | |
| N/A | 
| Apolipoprotein E Genotyping | |
| Apo E genotyping | |
| 4.7 ml EDTA tube (red top tube). Upon arrival in the laboratory the whole blood sample is stored at 4oC prior to referral (do not centrifuge) | |
| This test is referred to another centre for analysis: Centre for Haemostasis and Thrombosis 1st Floor North Wing St. Thomas' Hospital Lambeth Palace Road London SE1 7EH Tel: 020 718 2779 | |
| Used in the investigation of lipoprotein disorders | |
| Contact referal laboratory for information | |
| Contact referal laboratory for information | |
| N/A | |
| N/A | 
See Immunoglobulin E (Specific), Immunoglobulin G (Specific) and tryptase
| Aldosterone | |
| Aldosterone, Renin, PRA, ALDO | |
| 1x EDTA Plasma (red top) for Aldosterone Upon arrival in the laboratory the EDTA samples are centrifuged and the plasma stored frozen prior to referral. | |
| This test is referred to another centre: Department of Clinical Chemistry Expected turnaround time: 6 weeks | |
| Used in the investigation of suspected disorders of the adrenal glands | |
| Contact referal laboratory | |
| 100-450 pmol/L (Adults recumbent overnight). 100-800 pmol/L (Random sample or upright). | |
| N/A | |
| N/A | 
| Amiodarone | |
| Amiodarone, AMIO | |
| Serum (Brown). Upon receipt the sample is centrifuged and stored refrigerated prior to referral. | |
| This test is referred to another lab for analysis: Toxicology Laboratory  Tel: 029 2071 6894 Expected turnaround time: 6 weeks | |
| Used in the therapeutic drug monitoring of amiodarone | |
| Contact referal laboratory | |
| Contact referal laboratory | |
| N/A | |
| N/A | 
| Amino Acids | |
| Amino Acids, plasma, urine, urea cycle, AMINP, AMINU, metabolic screen | |
| Blood - li-hep plasma (orange bottle), Urine - 20ml universal container. Store refridgerated prior to referral Please note: serum (brown bottle) is not a suitable specimen type | |
| This test is referred to another centre: Department of Clinical Chemistry Expected turnaround time: 6 weeks | |
| Used in the the investigation of amino acid disorders, including urea cycle defects and some organic acid disorders. Please note: Urine amino acids is no longer used as a metabolic screen (please use plasma amino acids). It is available for the investigation of renal transport disorders (e.g. cystinuria), the assessment of renal tubular dysfunction (e.g. Fanconi syndrome, mitochondrial disease) and for some other specific disorders (e.g. hypophosphatasia). | |
| Contact referral laboratory | |
| Contact referral laboratory | |
| N/A | |
| N/A | 
| Assay | Alpha-fetoprotein | 
| Key Words | AFP | 
| Specimen Collection | Serum (brown) Plasma (orange) | 
| Turnaround Time | 72hrs | 
| Test Indications | AFP is an albumin like glycoprotein. AFP is used as a tumour marker for germ cell/testicular tumours and hepatocellular carcinomas. Germ cell/testicular tumours – used in diagnosis, prognosis, detecting recurrence and monitoring treatment. Hepatocellular carcinoma – used in screening at risk groups (patients with chronic hepatitis B/C or cirrhosis, in conjunction with ultrasonography), diagnosis (in conjunction with liver imaging a-fetoprotein levels of >200mg/L are virtually diagnostic in patients with hypervascular lesions), prognosis, detecting recurrence and monitoring treatment. Also raised in other cancers (colorectal, gastric, lung, pulmonary) and some benign conditions (liver regeneration). | 
| Limitations/Interferences | No known common methodological interferences. | 
| Reference Range | Less than 7 ng/mL | 
| 4.5% | |
| 36.6% | |
| Minimum retesting interval | Requests made within 14 days of a previous result on a patient are intervened | 
| Assay | Albumin (urine) | 
| Key Words | Microalbumin, MALB, albumin creatinine ratio, ACR | 
| Specimen Collection | Random urine sample in 20ml universal | 
| Turnaround time | 72hrs | 
| Test indications | Urine albumin creatinine ratio is the test of choice for the investigation of proteinuria. | 
| Interferences | No known interferences | 
| Reference Range | ACR >30mg/mmol creatinine indicates proteinuria. ACR >70mg/mmol indicates heavy proteinuria. Albumin excretion is expressed as a ratio to urinary creatinine to correct for urinary concentration. | 
| 3.5% | |
| 100.3% | |
| Minimum retesting interval | Requests made within 30 days of a previous result on a patient are intervened | 
| Assay | Alkaline Phosphatase | 
| Key Words | ALP, ALKP | 
| Specimen Collection | Serum (brown), Plasma (orange) | 
| Turnaround time | 8hrs | 
| Test indications | A rise in the alkaline phosphatase occurs with all forms of cholestasis, particularly with obstructive jaundice. It is also elevated in diseases of the skeletal system, such as Pagets disease, hyperparathyroidism, rickets and osteomalaecia, as well as with fractures and malignant tumours. A considerable rise in the alkaline phosphatase activity is sometimes seen in children and juveniles. It is caused by increased osteoblast activity following accelerated bone growth. | 
| Interferences | EDTA (from FBC bottles) can cause falsely low results, please ensure the correct draw order is adhered to | 
| Reference Range | Neonate: 70-380 U/L Infant to 16 yrs: 60-425 U/L Adult: 30-130 U/L | 
| 2.6% | |
| 16.3% | |
| Minimum retesting interval | Liver function test requests made within 2 days of a previous request on a patient are intervened | 
| Androstenidione | |
| Androstenidione, ANDI | |
| Serum (brown), Plasma (orange). Upon receipt in the laboratory the sample is centrifuged and the serum/plasma refrigerated prior to referral. | |
| This test is referred to another centre for analysis: Chemical Pathology Department Expected turnaround time: 6 weeks | |
| Used in the investigation of endocrinology disorders | |
| Contact referal laboratory | |
| Male: Pre-pubertal = <0.9 nmol/L, Post-pubertal = 1.5 - 8.3 nmol/L Female: Pre-pubertal = <0.9 nmol/L, Post-pubertal = 1.1 - 7.7 nmol/L | |
| N/A | |
| N/A | 
| Assay | ABL Kinase domain mutations | 
| Key Words | ABL, Kinase, Domain, Mutation | 
| Specimen Collection | 20ml peripheral blood EDTA. | 
| Referral | This test is referred to another centre for analysis: Laboratory for Molecular Haemato-Oncology (LMH) 
 King's College Hospital NHS Trust | 
| Turnaround time | 5 days from receipt at reference laboratory | 
| Test indications | To test for resistance to therapy with first line Tyrosine kinase inhibitors (Eg Imatinib, Nilotinib, Dasatinib) | 
| Interferences | Contact referral laboratory for information | 
| Reference Range | Contact referral laboratory for information | 
| Minimum retesting interval | N/A | 
| Assay | Abnormal Haemoglobin Referral (Globin chain analysis) | 
| Key Words | Haemoglobinopathy, haemoglobin variant globin chain analysis, DNA testing, thalassaemia | 
| Specimen Collection | 10ml EDTA. Patients should be aware that when giving us their family origin information and agreeing to antenatal family origin screening, we will where necessary provide this information to other healthcare professionals outside the Pathology department in order to provide appropriate antenatal care. | 
| Referral | This test is referred to another centre for analysis: North West Genomic Laboratory Manchester Centre for Genomic Medicine St Mary's Hospital Oxford Road Manchester M13 9WL | 
| Turnaround time | 6 weeks from receipt at reference laboratory | 
| Test indications | Determination globin chain specificity for thalassaemias | 
| Interferences | Contact referral laboratory for information | 
| Reference Range | Contact referral laboratory for information | 
| Minimum retesting interval | N/A | 
| Assay | Abnormal Haemoglobin Referral (Haemoglobin variant) | 
| Key Words | Haemoglobinopathy, haemoglobin variant, mass spectroscopy | 
| Specimen Collection | 7.5ml EDTA. Patients should be aware that when giving us their family origin information and agreeing to antenatal family origin screening, we will where necessary provide this information to other healthcare professionals outside the Pathology department in order to provide appropriate antenatal care. | 
| Referral | This test is referred to another centre for analysis: North West Genomic Laboratory Manchester Centre for Genomic Medicine St Mary's Hospital Oxford Road Manchester M13 9WL | 
| Turnaround time | 6 weeks from receipt at reference laboratory | 
| Test indications | Haemoglobinopathy of unknown specificity | 
| Interferences | Contact referral laboratory for information | 
| Reference Range | Contact referral laboratory for information | 
| Minimum retesting interval | N/A | 
| Adrenocorticotrophic hormone (ACTH) | |
| ACTH | |
| EDTA Plasma (red top). Specimen must be transported on ice and taken to the laboratory as soon as possible. Failure to comply with these instructions may result in the request being rejected, particularly if there are delays of over 4hrs. Upon arrival in the laboratory the sample is centrifuged and the plasma stored frozen prior to dispatch | |
| This test is referred to another centre: Department of Clinical Chemistry Expected turnaround time: 6 weeks | |
| Used in the investigation of pituitary-adrenal disorders relating to glucocorticoids | |
| Contact referal laboratory | |
| <50 ng/L at 9am | |
| N/A | |
| N/A | 
| Assay | Anderson-Fabry Disease Disease | 
| Key Words | Plasma α-galactosidase A activity, Anderson-Fabry Disease, Fabry disease | 
| Specimen Collection | 6ml-10ml EDTA (large EDTA) and 6-10ml Li-Heparin (large Li-Heparin) | 
| Referral | This test is referred to another centre for analysis: Willink Biochemical Genetics Laboratory 6th Floor, Pod 1 Saintt Mary's Hospital 
 Oxford Road Manchester M13 9WL | 
| Turnaround time | 14 days from receipt at reference laboratory for enzyme investigations 28 days from receipt at reference laboratory for genetic investigations | 
| Test indications | To exclude Anderson-Fabry Disease | 
| Interferences | Contact referral laboratory for information | 
| Reference Range | Contact referral laboratory for information | 
| Minimum retesting interval | N/A | 
| Assay | Alanine Aminotransferase | 
| Key Words | ALT | 
| Specimen Collection | Serum (brown), Plasma (orange) | 
| Turnaround time | 8hrs | 
| Test indications | Elevated serum ALT is found in hepatitis, cirrhosis, obstructive jaundice, carcinoma of the liver, and chronic alcohol abuse. ALT is only slightly elevated in patients who have an uncomplicated myocardial infarction. | 
| Interferences | Sulfasalazine and sulfapyradine at therapeutic concentrations may cause falsely low or high results. Please contact laboratory for further information on assay interferences | 
| Reference Range | Male <41 U/L Female <33 U/L | 
| 2.3% | |
| 26.6% | |
| Minimum retesting interval | Liver function test requests made within 2 days of a previous result on a patient are intervened | 
| Assay | Anti-Cytosolic 5’-nucleotidase 1A | 
| Key Words | NT5C1A, CN1A, Cytosolic 5’- Nucleotidase 1A | 
| Specimen Collection | Serum (Brown) | 
| Turnaround time | This test is referred to another centre: 
 Turnaround time is 10 working days 
 Referral centre Address 
 Immunology Herschel Building Level B38 Blood Sciences Royal United Hospital Bath NHS Foundation Trust Combe Park Bath BA1 3NG 
 
 | 
| Test indications | Anti-Cytosolic 5’-nucleotidase 1A antibodies are associated with inclusion body myositis. 
 Inclusion body myositis is a progressive muscle disorder characterised by muscle inflammation, weakness, and atrophy. It is a type of inflammatory myopathy. IBM develops in adulthood usually after age of 50. The symptoms and rate of progression vary. 
 | 
| Methodology | Immunoblotting | 
| Interferences | Contact referral centre | 
| Reference Range | Contact referral centre | 
| Analytical error | Contact referral centre | 
| Reference change value | Contact referral centre | 
| Acylcarnitines | |
| Acylcarnitines, total carnitines | |
| Blood spot (Guthrie Card) or Lithium-heparin sample (unspun) | |
| This test is referred to another centre: Department of Clinical Chemistry Expected turnaround time: 6 weeks | |
| Used in the investigation of disorders of fatty acid chain oxidation | |
| Contact referral laboratory | |
| C0 Free Carnitine C2 Acetyl Carnitine C3 Propionyl Carnitine C4 Butyryl Carnitine C5 Isovaleryl Carnitine C6 Hexanoyl Carnitine C8 Octanoyl Carnitine C10 Decanoyl Carnitine C14 Myristoyl Carnitine C16 Palmitoyl Carnitine | |
| N/A | |
| N/A | 
| Assay | Apixaban | 
| Key Words | Direct Xa inhibitor, Apixaban | 
| Specimen Collection | 3.0ml Citrate (Green lid). 1.4ml Citrate for paediatric (Green lid). Fill to mark. Samples shoule ideally be received by the laboratory within 3 hours of collection. | 
| Turnaround time | Next working day | 
| Test indications | Apixaban dose monitoring | 
| Interferences | Apixaban levels change markedly over time owing to the pharmacokinetics of the drug (e.g. levels of apixaban will differ greatly 2–4 hours versus 12 hours after dosing). Interpret results with caution. Discuss with Consultant Haematologist if necessary. | 
| Reference Range | See table below. Discuss with Consultant Haematologist if necessary. | 
| Minimum retesting interval | N/A | 
| Dose (mg) | Trough (ng/mL) | Peak (ng/mL) | 
| 2.5,g twice daily 
 | 20-94 | 36-100 | 
| 10mg twice daily 
 | 31-412 | 122-412 | 
Gosselin RC, Adcock DM. The laboratory’s 2015 perspective on direct oral anticoagulant testing. J Thromb Haemost 2016; 14: 886-93.
| Assay | Albumin (Serum/Plasma) | 
| Key Words | Albumin | 
| Specimen Collection | Serum (brown), Plasma (orange) | 
| Turnaround time | 8hrs | 
| Test indications | Albumin is a key plasma protein. Low levels are seen in liver disease, burns, malabsorption, and is losses through the kidneys (proteinuria) and stool. Raised levels usually indicate dehydration. | 
| Interferences | No known methodological interferences | 
| Reference Range | • <1 year: 30-45 g/L • <17 years: 30-50 g/L 
 • ≥17 years: 35-50 g/L | 
| 2.2% | |
| 8.9% | |
| Minimum retesting interval | Liver function test requests made within 2 days of a previous result on a patient are intervened | 
| Assay | Anti Thyroid Peroxidase | 
| Key Words | aTPO, TPO | 
| Specimen Collection | Serum (brown), Plasma (orange) | 
| Turnaround Time | 24hrs | 
| Test Indications | Anti-TPO is used to investigate the presence of autoimmune thyroiditis (e.g. Hashimotos' thyroiditis and Grave's Disease). The measurement of thyroid antibodies in subjects with subclinical hypothyroidism helps to define the risk of developing overt hypothyroidism | 
| Limitations/Interferences | No known common methodological interferences. | 
| Reference Range | <35 IU/mL | 
| 7.1% | |
| 25.7% | |
| Minimum retesting interval | Repeat testing of Anti-TPO within 12 months is not usually indicated, and repeat tests within this timeframe are intervened. If you require a repeat test please contact the laboratory prior to requesting. | 
| Assay | Acetylcholine receptor antibodies (ACRA) | 
| Key Words | Acetylcholine receptor antibodies ACRA, Myasthenia gravis Panel | 
| Specimen Collection | Serum (brown) | 
| Turnaround time | Contact referral centre for Turnaround time 
 This test is referred to another centre: 
 Department of Immunology The Churchill Hospital Headington Oxford OX3 7LJ 
 Tel: 01865 225995 
 | 
| Test indications | IgG Anti-AChR antibodies are found in 80-90% of subjects with myasthenia gravis, and 60% of those with ocular myasthenia. They are virtually never found in the normal population, but are seen in 3-10% of unaffected first degree relatives of myasthenic patients. 50% of patients with non-myasthenic thymoma are positive, and in 4% of patients on penicillamine with no clinical evidence of myasthenia. The majority of neonates born to seropositive myasthenic mothers are transiently anti-AChR positive due to passive transfer of maternal immunoglobulin, however only a small percentage develop clinical neonatal myasthenia. Please Note: MuSK antibodies may be useful in patients with a convincing history of myasthenia who are negative for AChR antibodies. | 
| Methodology | Indirect immunofluoresence | 
| Interferences | Contact referral laboratory | 
| Reference Range | 
 Contact referral laboratory 
 | 
| Analytical error | Contact referral laboratory | 
| Reference change value | N/A | 
| Assay | Alpha-Amino-3-Hydroxyl-5-Methyl-4-Isoxazolepropionic acid antibodies (AMPA/GABB) | 
| Key Words | AMPA receptor antibodies, Glutamate receptor antibodies profile (GABB) | 
| Specimen Collection | Serum (Brown) | 
| Turnaround time | 14 Days 
 This test is referred to another centre: Churchill Hospital Old Road Headington Oxford OX3 7LE 0300 304 7777 
 | 
| Test indications | AMPA receptors are glutamate receptors that mediate fast excitatory neurotransmission in the brain. Antibodies targeting the extracellular domains of either or both GluR1 or GluR2 subunits have been associated with limbic encephalitis. | 
| Methodology | Cell based assay | 
| Interferences | Contact referral laboratory | 
| Reference Range | N/A | 
| Analytical error | Contact referral laboratory | 
| Reference change value | N/A | 
| Assay | Adalimumab (ADALIM) | 
| Key Words | Adalimumab , Adalimumab antibodies | 
| Specimen Collection | Serum (Brown) | 
| Turnaround time | 
 14 days 
 This test is referred to another centre: Department of Clinical Biochemistry City Hospital Dudley road Birmingham B18 7QH 0121 507 3441 
 | 
| Test indications | Adalimumab is a humanised monoclonal antibody directed against tumour necrosis factor alpha (TNF). Anti-TNF therapy has become an important alternative treatment in the management of patients with chronic inflammatory diseases such as rheumatoid arthritis (RA), Crohn’s disease (CD), and ankylosing spondylitis (AS). 
 The relationship between serum trough levels of anti-TNF drug and clinical improvement has been identified indicating that it can be used as a therapeutic monitoring tool. Within a given population of patients a significant number have been noted to develop resistance to the drug and show undetectable trough levels of Adalimumab. 
 The main indication for undertaking the test is lack of clinical response to the Adalimumab. A trough serum concentration of <5 µg /mL, in a patient on Adalimumab, indicates subtherapeutic levels. If anti-drug antibodies are present, a change in drug therapy should be considered. In patients with low levels of Adalimumab but absent antibodies, a review of the treatment regimen may be required once non-compliance has been excluded. 
 Antibodies will only be tested if indicated by a trough serum concentration of <5.0 µg/mL 
 | 
| Methodology | ELISA | 
| Interferences | Contact referral lab | 
| Reference Range | Trough therapeutic cut-off : >5.0 µg/mL | 
| Analytical error | Contact referral lab | 
| Reference change value | Contact referral lab | 
| Assay | Adrenal cortical antibodies | 
| Key Words | Adrenal cortical antibodies, adrenal antibodies (ADRA) | 
| Specimen Collection | Serum (brown) | 
| Turnaround time | 10 days This test is referred to another centre: Department of Clinical Chemistry and Immunology Level 4 | 
| Test indications | 
 Anti-adrenal antibodies are found in 60% of patients with idiopathic hypoadrenalism where they are directed against the enzyme 21-hydroxylase, and in 90% of those with hypoadrenalism in association with ovarian failure (Autoimmune Polyglandular Syndrome-1, APS-1) where they react with 17-hydroxylase and the side chain cleaving enzyme complex involved in steroid bio-synthesis. They are found in <0.1% of the normal population. The titre of antibody is of no significance, and so is not measured. As the adrenal gland atrophies the antibodies may disappear so sequential follow-up is not useful. | 
| Methodology | Indirect immunofluorescence | 
| Interferences | Contact referral laboratory | 
| Reference Range | N/A | 
| Analytical error | N/A | 
| Reference change value | N/A | 
| Assay | Aquaporin-4 antibodies (anti-NMO antibodies) | 
| Key Words | Aquaporin abs (AQUS) | 
| Specimen Collection | Serum (brown) | 
| Turnaround time | 14 days 
 This test is referred to another centre: 
 Department of Immunology The Churchill Hospital Headington Oxford OX3 7LJ Tel: 01865 225995 Fax: 01865 225990 | 
| Test indications | This test is indicated for patients suspected to have neuromyelitis optica (also called Devic's disease) which causes pain in the eye and vision loss. Transverse myelitis is also associated which causes weakness, numbness, and sometimes paralysis of the arms and legs, along with sensory disturbances and loss of bladder and bowel control. | 
| Methodology | Contact referral centre | 
| Interferences | Contact referral centre | 
| Reference Range | N/A | 
| Analytical error | Contact referral centre | 
| Reference change value | N/A | 




